Evidence map›Paper›PMID 39341996›Full record

ArticleAnnals of nuclear medicine2025

Raef R Boktor, Salvatore U Berlangieri, Eddie Lau, Adeline Lim, Sylvia J Gong, Xia Li, Andrew M Scott

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Raef R BoktorDepartment of Molecular Imaging and Therapy, Austin Health, 145 Studley Rd, Heidelberg, Melbourne, VIC, 3084, Australia. Raef.Boktor@austin.org.au.ORCID http://orcid.org/0000-0003-4861-619X
Salvatore U BerlangieriDepartment of Molecular Imaging and Therapy, Austin Health, 145 Studley Rd, Heidelberg, Melbourne, VIC, 3084, Australia.
Eddie LauDepartment of Molecular Imaging and Therapy, Austin Health, 145 Studley Rd, Heidelberg, Melbourne, VIC, 3084, Australia.
Adeline LimDepartment of Radiation Oncology, Austin Health, Melbourne, VIC, Australia.
Sylvia J GongDepartment of Molecular Imaging and Therapy, Austin Health, 145 Studley Rd, Heidelberg, Melbourne, VIC, 3084, Australia.
Xia LiDepartment of Mathematical and Physical Sciences, La Trobe University, Melbourne, VIC, Australia.
Andrew M ScottDepartment of Molecular Imaging and Therapy, Austin Health, 145 Studley Rd, Heidelberg, Melbourne, VIC, 3084, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionStereotactic ablative body radiotherapy (SABR) is a standard treatment option for patients with malignant pulmonary masses (including primary and metastatic lesions) who are unfit for surgery or who are medically operable but refuse surgery. Flourine-18 flurodeoxyglucose positron emission tomography (

objectivesThe aim of this retrospective study is to assess the value of baseline metabolic volumetric parameters as prognostic imaging biomarkers in patients with pulmonary masses/nodules treated with SABR.

methods70 patients were included in this retrospective study (39 male and 31 female, age range 47-91 years, mean 76 years). Standardized uptake value (SUVmax), SUVmean, MTV and TLG for all the patients were calculated on baseline

resultsThere was no significant statistical difference in the SUVmax and SUVmean in all the three categories. Mean SUVmax ranges from 7.13 to 8.08 with its highest value in the stable disease and lowest value in the progressive disease categories. Similarly, the average SUVmean was 4.9 in the free of disease category and 4.68 in the progressive disease category. MTV and TLG were low in the free of disease and the highest in progressive disease. MTV increased from 2.25 cm

conclusionsTLG and MTV are more useful than SUVmax and SUVmean for predicting outcome, OS and progression-free survival (PFS) in patients receiving SABR. The TLG and MTV measurement on

Indexed as

Fluorodeoxyglucose F18Lung NeoplasmsPositron Emission Tomography Computed TomographyRadiosurgeryAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateTreatment OutcomeFluorodeoxyglucose F1818F-FDG PET/CTPulmonary nodulesSABRTLG and MTV

Identifiers

PMID39341996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.